Avidity Biosciences (RNA) Competitors $46.35 +1.69 (+3.78%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$46.45 +0.10 (+0.22%) As of 08/22/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA vs. INSM, SMMT, TEVA, GMAB, ASND, RDY, VTRS, QGEN, MRNA, and VRNAShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), QIAGEN (QGEN), Moderna (MRNA), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Avidity Biosciences vs. Its Competitors Insmed Summit Therapeutics Teva Pharmaceutical Industries Genmab A/S Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris QIAGEN Moderna Verona Pharma PLC American Depositary Share Avidity Biosciences (NASDAQ:RNA) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Is RNA or INSM more profitable? Insmed has a net margin of -259.82% compared to Avidity Biosciences' net margin of -4,247.77%. Avidity Biosciences' return on equity of -33.45% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-4,247.77% -33.45% -30.22% Insmed -259.82%-195.37%-49.49% Do analysts prefer RNA or INSM? Avidity Biosciences currently has a consensus price target of $67.00, suggesting a potential upside of 44.55%. Insmed has a consensus price target of $132.57, suggesting a potential upside of 0.52%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Avidity Biosciences is more favorable than Insmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.06Insmed 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.94 Does the media prefer RNA or INSM? In the previous week, Insmed had 32 more articles in the media than Avidity Biosciences. MarketBeat recorded 47 mentions for Insmed and 15 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.00 beat Insmed's score of 0.89 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 18 Very Positive mention(s) 8 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, RNA or INSM? Avidity Biosciences has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$10.90M547.06-$322.30M-$3.56-13.02Insmed$363.71M76.65-$913.77M-$5.71-23.10 Which has more volatility and risk, RNA or INSM? Avidity Biosciences has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. SummaryAvidity Biosciences beats Insmed on 11 of the 14 factors compared between the two stocks. Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.75B$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio-13.0221.2831.3026.05Price / Sales547.06345.81432.98193.75Price / CashN/A43.1937.7358.48Price / Book5.008.129.536.61Net Income-$322.30M-$54.72M$3.26B$265.65M7 Day Performance-0.26%2.62%2.13%2.02%1 Month Performance36.65%2.68%2.80%-0.31%1 Year Performance6.50%10.93%30.68%19.06% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences3.1707 of 5 stars$46.35+3.8%$67.00+44.6%+8.2%$5.75B$10.90M-13.02190Positive NewsInsider TradeOptions VolumeINSMInsmed4.0044 of 5 stars$112.89+3.0%$112.71-0.2%+66.9%$23.16B$363.71M-19.771,271Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionSMMTSummit Therapeutics2.3705 of 5 stars$28.25-1.4%$34.67+22.7%+93.8%$21.28B$700K-83.09110Analyst ForecastTEVATeva Pharmaceutical Industries3.4244 of 5 stars$16.41+0.3%$24.71+50.6%+0.4%$18.78B$16.54B-102.5836,830Positive NewsGMABGenmab A/S3.8549 of 5 stars$21.08-1.6%$37.80+79.3%-8.8%$13.75B$3.12B10.592,682Analyst DowngradeASNDAscendis Pharma A/S3.4374 of 5 stars$195.97+2.3%$239.80+22.4%+39.4%$11.71B$393.54M-37.981,017News CoverageAnalyst ForecastRDYDr. Reddy's Laboratories3.1016 of 5 stars$13.81+0.0%$16.95+22.8%-12.1%$11.52B$3.81B20.9227,811News CoveragePositive NewsVTRSViatris1.6252 of 5 stars$9.86+1.6%$10.40+5.5%-9.0%$11.38B$14.74B-3.4032,000Analyst UpgradeHigh Trading VolumeQGENQIAGEN3.8201 of 5 stars$48.02-0.1%$49.69+3.5%+9.4%$10.68B$1.98B28.375,765MRNAModerna4.5019 of 5 stars$25.47-2.5%$43.59+71.1%-66.5%$10.16B$3.24B-3.385,800News CoverageAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.4034 of 5 stars$105.240.0%$109.00+3.6%+290.2%$8.96B$42.28M-106.3030Short Interest ↓ Related Companies and Tools Related Companies Insmed Competitors Summit Therapeutics Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Ascendis Pharma A/S Competitors Dr. Reddy's Laboratories Competitors Viatris Competitors QIAGEN Competitors Moderna Competitors Verona Pharma PLC American Depositary Share Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNA) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access